You just read:

The FDA removes the contraindication for use of Bracco Diagnostics Inc.'s LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use, in patients with cardiac shunts

News provided by

Bracco Diagnostics Inc.

11 Jan, 2017, 08:00 ET